Atai Life Sciences N.V.
ATAI
$4.05
-$0.125-3.00%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.56M | -5.00K | 40.00K | 273.00K | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.56M | -5.00K | 40.00K | 273.00K | -- |
| Cost of Revenue | 10.84M | -- | -- | -- | 11.23M |
| Gross Profit | -9.28M | -5.00K | 40.00K | 273.00K | -11.23M |
| SG&A Expenses | 9.99M | 11.44M | 10.27M | 13.40M | 10.96M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.83M | 29.34M | 22.64M | 26.00M | 22.19M |
| Operating Income | -19.27M | -29.35M | -22.60M | -25.73M | -22.19M |
| Income Before Tax | -26.34M | -39.71M | -26.49M | -57.35M | -27.59M |
| Income Tax Expenses | 128.00K | -718.00K | -178.00K | 19.00K | -209.00K |
| Earnings from Continuing Operations | -26.47M | -38.99M | -26.31M | -57.37M | -27.38M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 34.00K | 33.00K | 25.00K | 57.00K | 665.00K |
| Net Income | -26.43M | -38.96M | -26.29M | -57.31M | -26.71M |
| EBIT | -19.27M | -29.35M | -22.60M | -25.73M | -22.19M |
| EBITDA | -19.05M | -29.12M | -22.52M | -25.65M | -22.10M |
| EPS Basic | -0.15 | -0.24 | -0.16 | -0.36 | -0.17 |
| Normalized Basic EPS | -0.12 | -0.12 | -0.11 | -0.22 | -0.13 |
| EPS Diluted | -0.15 | -0.24 | -0.16 | -0.36 | -0.17 |
| Normalized Diluted EPS | -0.12 | -0.12 | -0.11 | -0.22 | -0.13 |
| Average Basic Shares Outstanding | 176.27M | 160.71M | 160.62M | 160.39M | 158.89M |
| Average Diluted Shares Outstanding | 176.27M | 160.71M | 160.62M | 160.39M | 158.89M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |